NCT02147418 is a clinical trial in Oropharyngeal Cancer, sponsored by New Mexico Cancer Research Alliance.

Who is sponsoring NCT02147418?

NCT02147418 is sponsored by New Mexico Cancer Research Alliance.

What condition does NCT02147418 study?

NCT02147418 studies Oropharyngeal Cancer.

Is NCT02147418 still recruiting?

NCT02147418 is currently completed. Last updated 22 May 2025.

Last reviewed 2025-05-22 · How we verify

NCT02147418

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma

Completed Last updated 22 May 2025

What this trial tests

trial in Oropharyngeal Cancer in 15 participants. Completed in 25 July 2024.

Timeline

25 February 2015

Primary endpoint
8 May 2024

25 July 2024

Quick facts

Lead sponsor	New Mexico Cancer Research Alliance
Status	Completed
Study type	OBSERVATIONAL
Enrollment	15
Start date	25 February 2015
Primary completion	8 May 2024
Estimated completion	25 July 2024
Sites	1 location across United States

Conditions studied

Oropharyngeal Cancer — all drugs for Oropharyngeal Cancer →

Sponsor

New Mexico Cancer Research Alliance — full company profile →

Who can join

18 and older, any sex, with Oropharyngeal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cancer of the oropharynx (middle, side and back walls of the throat; back of the tongue; soft palate, and tonsils), or oropharyngeal squamous cell carcinoma (OPSCC), has been on the rise in the United States. Human papillomavirus (HPV) has been recognized in many of these cancers, and testing for HPV has contributed to the higher reported rates of OPSCC. In this study, our goal is to develop a new test that can detect certain HPV proteins in the blood or saliva to help improve detection of OPSCC.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Extracellular vesicles as tools and targets in therapy for diseases.
Kumar MA, Baba SK, Sadida HQ, Marzooqi SA, et al · · 2024 · cited 686× · PMID 38311623 · DOI 10.1038/s41392-024-01735-1
Cancer-Derived Exosomes: Their Role in Cancer Biology and Biomarker Development.
Kok VC, Yu CC. · · 2020 · cited 318× · PMID 33116515 · DOI 10.2147/ijn.s272378
The Origin and Functions of Exosomes in Cancer.
Rajagopal C, Harikumar KB. · · 2018 · cited 209× · PMID 29616188 · DOI 10.3389/fonc.2018.00066
Exosomes as Reconfigurable Therapeutic Systems.
Conlan RS, Pisano S, Oliveira MI, Ferrari M, et al · · 2017 · cited 170× · PMID 28648185 · DOI 10.1016/j.molmed.2017.05.003
Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications.
Huda MN, Nafiujjaman M, Deaguero IG, Okonkwo J, et al · · 2021 · cited 160× · PMID 33988964 · DOI 10.1021/acsbiomaterials.1c00217
Tumor-derived exosomes in cancer progression and treatment failure.
Yu S, Cao H, Shen B, Feng J. · · 2015 · cited 159× · PMID 26452221 · DOI 10.18632/oncotarget.6022
Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications.
He G, Peng X, Wei S, Yang S, et al · · 2022 · cited 147× · PMID 35039054 · DOI 10.1186/s12943-021-01440-5
Exosomes in Viral Disease.
Anderson MR, Kashanchi F, Jacobson S. · · 2016 · cited 134× · PMID 27324390 · DOI 10.1007/s13311-016-0450-6

Verify or expand the search:

Other recruiting trials for Oropharyngeal Cancer

Currently open trials in the same condition.

NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06446713 — PIRATES: Image-guided Hyper-fractioned Dose-escalation With Proton Therapy for Head and Neck Cancer · Phase 1 · recruiting
NCT06747390 — Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery · Phase 1 · recruiting
NCT05363709 — BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients · Phase 2 · active not recruiting
NCT05862792 — Liposomal Bupivacaine and Transoral Robotic Surgery · recruiting

Other New Mexico Cancer Research Alliance trials

Trials by the same sponsor.

NCT07436793 — Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial · Phase 2 · not yet recruiting
NCT06260332 — Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors · NA · active not recruiting
NCT06207864 — Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing · NA · recruiting
NCT05176743 — Food Insecurity in Oncology · NA · completed
NCT04259762 — Enhancing Cancer Prevention and Control Pathways-Native Health Initiative · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02147418 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by New Mexico Cancer Research Alliance
Last refreshed: 22 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02147418.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing